0000000000238563
AUTHOR
A Azzolina
Gene expression profiling of human liver cancer cells following celecoxib tretment
Altered gene expression profiles in liver cancer cells upon sorafenib treatment
Development of nimesulide loaded solid lipid nanoparticles.
Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells
Background: In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and among them, the expression of the epidermal growth factor receptor (EGFR). Tyrphostin AG-1478 is a lipophilic low molecular weight inhibitor of EGFR, preferentially acting on liver tumor cells. In order to overcome its poor drug solubility and thus improving its anticancer activity, it was entrapped into nanostructured lipid carriers (NLC) by using safe ingredients for parenteral delivery. Results: Nanostructured lipid carriers (NLC) carrying tyrphostin AG-1478 were prepared by using the nanoprecipitation method and different matrix compositions. The best system in terms of mean size, PDI, zeta…
ENTRAPMENT OF TYRPHOSTIN AG 14-78 INTO LIPID NANOPARTICLES IMPROVES ITS ANTITUMOR ACTIVITY AGAINST HUMAN HEPATOCARCINOMA CELLS
The novel NF-kB inhibitor DHMEQ suppresses the growth of human hepatic cancer cells though redox-dependent signaling
Encapsulation of sorafenib into lipid nanoparticles improves its antitumor activity.
Effects of kind and amount of surfactants on physical-chemical properties of cationic solid lipid nanoparticles (SLN) for the treatment of hepatocellular carcinoma.
Lipid nanocarrier for the treatment of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause of cancer-related death. Unlike most solid tumors the incidence and mortality of HCC have increased in the United States and Europe in the past decade. Most patients are diagnosed at advanced stages, so there is an urgent need for new systemic therapies [1,2]. To improve the delivery of therapeutic agents to tumor cells in vivo it’s necessary to overcome several problems, such as drug resistance at the tumor level due to physiological barriers (non cellular based mechanism), drug resistance at the cellular level (cellular mechanism), drug distribution, biotransformation and clearance of antic…